TESTOSTERONE solution

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Veiklioji medžiaga:

TESTOSTERONE (UNII: 3XMK78S47O) (TESTOSTERONE - UNII:3XMK78S47O)

Prieinama:

Bryant Ranch Prepack

Vartojimo būdas:

TOPICAL

Recepto tipas:

PRESCRIPTION DRUG

Terapinės indikacijos:

Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Limitations of use: Pregnancy Category X [see Contraindications (4) ] — Testosterone Topical Solution is contraindicated during pregnancy or in women who may become pregnant. Testosterone is teratogenic and may cause fetal harm. Exposure of a female fetus to androgens may result in varying degrees of virilization. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Although it is not known how much testosterone transfers into human milk, Testosterone Topical Solution is contraindicated in nursing women because of the potential for serious adverse reactions in nursing infants. Testosterone and other androgens may adversely affect lactation. [See Contraindications (4) ]. Safety and efficacy of Testosterone Topical Solution has not been established in males <18 years of age. Improper use may result in acceleration of bone age and premature closure of epiphyses. There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing testosterone topical solution to determine whether efficacy in those over 65 years of age differs from younger patients. Of the 155 patients enrolled in the pivotal clinical study utilizing testosterone topical solution, 21 were over 65 years of age. Additionally, there were insufficient long-term safety data in these patients utilizing testosterone topical solution to assess a potential incremental risk of cardiovascular disease and prostate cancer. No formal studies were conducted involving patients with renal impairment. No formal studies were conducted involving patients with hepatic impairment. Safety and efficacy of Testosterone Topical Solution in males with BMI >35 kg/m2 has not been established. Testosterone Topical Solution contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. Abuse-Related Adverse Reactions Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Behaviors Associated with Addiction Continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented. TESTOSTERONE (tes-TOS-te-rone) topical solution USP, for topical use CIII Read this Instructions for Use for Testosterone Topical Solution before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment. Applying Testosterone Topical Solution: Find Your Dose as Prescribed by Your Healthcare Provider Each application equals 1 press (depression) of the pump. 30 mg Apply 1 application one time, to one armpit only (left or right). 60 mg Apply 2 applications: one to the left armpit and then one to the right armpit. 90 mg Apply 3 applications: one to the left and one to the right armpit, wait for the product to dry, and then apply again one to the left or right armpit. 120 mg Apply 4 applications: one to the left and one to the right armpit, wait for the product to dry, and then apply again one to the left and one to the right armpit. Figure 2 How should I store Testosterone Topical Solution? Keep Testosterone Topical Solution and all medicines out of the reach of children. Revised: 06-20

Produkto santrauka:

16.1 How Supplied Testosterone Topical Solution USP, 30 mg/1.5 mL is available as a metered-dose pump containing 110 mL of solution. The pump is capable of dispensing 90 mL of solution in 60 metered pump actuations. One pump actuation delivers 30 mg of testosterone in 1.5 mL of solution. Each metered-dose pump is supplied with an applicator. The bottle and the applicator cup are not made with natural rubber latex. NDC 63629-9310-1 16.2 Storage and Handling Keep Testosterone Topical Solution out of reach of children. Store upright at 25°C (77°F). Excursions are permitted to 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Used Testosterone Topical Solution bottles and applicators should be discarded in household trash in a manner that prevents accidental exposure of children or pets. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Autorizacija statusas:

Abbreviated New Drug Application

Pakuotės lapelis

TESTOSTERONE- TESTOSTERONE SOLUTION
Bryant Ranch Prepack
----------
MEDICATION GUIDE
TESTOSTERONE (tes-TOS-te-rone)
topical solution USP, for topical use CIII
What is the most important information I should know about
Testosterone Topical Solution?
1. Testosterone Topical Solution can transfer from your body to others
including, children and women.
Children and women should avoid contact with the unwashed or not
covered (unclothed) areas where
Testosterone Topical Solution has been applied to your skin. Early
signs and symptoms of puberty have
occurred in young children who have come in direct contact with
testosterone by touching areas where men
have used Testosterone Topical Solution.
Children
Signs and symptoms of early puberty in a child when they come in
direct contact with Testosterone Topical
Solution may include:
Abnormal sexual changes:
•
enlarged penis or clitoris.
•
early growth of hair near the vagina or around the penis (pubic hair).
•
erections or acting out sexual urges (sex drive).
Behavior problems:
•
acting aggressively, behaving in an angry or violent way.
Women
Signs and symptoms in women when they come in direct contact with
Testosterone Topical Solution
may include:
•
changes in body hair.
•
an abnormal increase in pimples (acne).
Stop using Testosterone Topical Solution and call your healthcare
provider right away if you see any signs
and symptoms in a child or a woman that may have happened through
accidental touching of the area where
you have applied Testosterone Topical Solution:
2. To lower the risk of transfer of Testosterone Topical Solution from
your body to others, follow these
important instructions:
•
Apply Testosterone Topical Solution only to your armpits.
•
Wash your hands right away with soap and water after applying
Testosterone Topical Solution.
•
After the solution has dried, cover the application area with
clothing. Keep the area covered until
you have washed the application area well or have showered.
•
If you expect to have skin-to-skin contact with

Prekės savybės

TESTOSTERONE- TESTOSTERONE SOLUTION
BRYANT RANCH PREPACK
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
TESTOSTERONE TOPICAL
SOLUTION SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING INFORMATION FOR TESTOSTERONE TOPICAL SOLUTION.
TESTOSTERONE TOPICAL SOLUTION, FOR TOPICAL USE CIII
INITIAL U.S. APPROVAL: 1953
WARNING: SECONDARY EXPOSURE TO TESTOSTERONE
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•VIRILIZATION HAS BEEN REPORTED IN CHILDREN WHO WERE SECONDARILY
EXPOSED TO TOPICAL
TESTOSTERONE PRODUCTS (5.2)•CHILDREN SHOULD AVOID CONTACT WITH
UNWASHED OR UNCLOTHED
APPLICATION SITES IN MEN USING TESTOSTERONE TOPICAL SOLUTION, 30
MG/1.5 ML (2.2,
5.2)•HEALTHCARE PROVIDERS SHOULD ADVISE PATIENTS TO STRICTLY ADHERE
TO RECOMMENDED
INSTRUCTIONS FOR USE (2.2, 5.2, 17)
INDICATIONS AND USAGE
Testosterone Topical Solution, 30 mg/1.5 mL is indicated for
replacement therapy in males for conditions
associated with a deficiency or absence of endogenous testosterone:
(1)
•
•
Limitations of use: (1)
•
•
DOSAGE AND ADMINISTRATION
Prior to initiating Testosterone Topical Solution, 30 mg/1.5 mL,
confirm the diagnosis of hypogonadism by
ensuring that serum testosterone has been measured in the morning on
at least two separate days and
that these concentrations are below the normal range (2). (2)
•
•
•
•
•
DOSAGE FORMS AND STRENGTHS
Testosterone Topical Solution, 30 mg/1.5 mL is available as a
metered-dose pump. One pump actuation
delivers 30 mg of testosterone. Each metered-dose pump is supplied
with an applicator. (3) (3)
CONTRAINDICATIONS
Primary hypogonadism (congenital or acquired) (1)
Hypogonadotropic hypogonadism (congenital or acquired) (1)
Safety and efficacy of Testosterone Topical Solution, 30 mg/1.5 mL in
men with “age-related
hypogonadism” have not been established. (1)
Safety and efficacy of Testosterone Topical Solution, 30 mg/1.5 mL in
males <18 years old have not
been established. (8.4)
Starting Testosterone Topi